Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) (NCT06651281)
A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, and if people tolerate it.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (4 items).
Location: Connecticut Clinical Research Institute ( Site 0297) — Bristol, Connecticut
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Has prematurely discontinued study intervention in their parent study
- Has received any protocol-specified prohibited medications during their parent study
- Has known allergies, hypersensitivity, or intolerance to tulisokibart or its excipients
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- Connecticut Clinical Research Institute ( Site 0297) — Bristol, Connecticut
- St. Joseph Mercy Hospital - Huron Gastroenterology Associates ( Site 0287) — Ypsilanti, Michigan
- BVL Research - Kansas ( Site 0292) — Liberty, Missouri
- New York Gastroenterology Associates ( Site 0253) — New York, New York
- GI Alliance - Digestive Health Associates of Texas - DHAT ( Site 0290) — Garland, Texas
- GI Alliance - Lubbock ( Site 0288) — Lubbock, Texas
- Caprock Gastro Research ( Site 0293) — Lubbock, Texas
- Southern Star Research Institute ( Site 0299) — San Antonio, Texas
- GI Alliance - Southlake ( Site 0298) — Southlake, Texas
- Tyler Research Institute ( Site 0294) — Tyler, Texas
- University of Virginia Health System ( Site 0291) — Charlottesville, Virginia
- Washington Gastroenterology - Tacoma ( Site 0295) — Tacoma, Washington
- Vojenská Nemocnice Brno-Internal department ( Site 0701) — Brno, Brno-mesto
- Hepato-Gastroenterologie HK ( Site 0700) — Hradec Králové,
- Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 1002) — Nice, Alpes-Maritimes
- CMC Ambroise Paré Hartmann - Institut des MICI ( Site 1003) — Neuilly-sur-Seine, Hauts-de-Seine
- CHRU De Nancy - Hopital de Brabois ( Site 1001) — Vandœuvre-lès-Nancy, Meurthe-et-Moselle
- Hopital Claude Huriez CHRU LILLE ( Site 1004) — Lille, Nord
- ARENSIA Exploratory Medicine Georgia ( Site 1104) — Tbilisi,
- Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház-4. Belgyogyaszat Gasztroenterologia ( Site 1411) — Békéscsaba, Bekes County
- Semmelweis Egyetem ( Site 1400) — Budapest,
- Rivermed Sp. z.o.o. ( Site 2206) — Poznan, Greater Poland Voivodeship
- Centrum Diagnostyczno - Lecznicze Barska sp. z o.o. ( Site 2208) — Włocławek, Kuyavian-Pomeranian Voivodeship
- Krakowskie Centrum Medyczne ( Site 2210) — Krakow, Lesser Poland Voivodeship
- Centrum Medyczne Oporow ( Site 2212) — Wroclaw, Lower Silesian Voivodeship
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohn Disease
- Precise Infliximab Exposure and Pharmacodynamic Control — Los Angeles, California
- Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease. — Winnipeg, Manitoba
- Standardized Microbiota Transplant Therapy in Crohn's Disease — Minneapolis, Minnesota
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Chandler, Arizona
- Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease — Lutherville, Maryland
- Threonine Requirement in Adult Males With Crohn's Disease Using IAAO — Toronto, Ontario
Explore by condition: All Crohn Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.